kabutan

HISAMITSU PHARMACEUTICAL CO.,INC., First Half Ordinary Profit Decreases by 7%

Thu Oct 10, 2024 3:00 pm JST Earnings

4530 HISAMITSU PHARMACEUTICAL CO.,INC. 【J-GAAP】

Earnings Report

HISAMITSU PHARMACEUTICAL CO.,INC. <4530> [TSE-P] announced its financial results after the market closed on October 10th (15:00). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending February 2025 (March to August) decreased by 7.3% from the same period last year to 10.7 billion yen. However, The progress rate against the 18.9 billion yen full-year plan was 57.1%, also surpassing the five-year average of 51.4%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the September to February period (second half) is expected to grow by 1.3% from the same period last year, reaching 8.11 billion yen.

In the most recent three-month period, from June to August (2Q), the consolidated ordinary profit decreased to 5.22 billion yen, a 11.8% decrease compared to the same period last year. However, the operating profit margin rose from 11.6% in the same period last year to 12.3%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Mar - Aug, 2022 59,619 4,913 8,870 6,504 81.6 55.3 Oct 12, 2022 J-GAAP
Mar - Aug, 2023 66,977 8,396 11,640 8,417 108.3 59.2 Oct 6, 2023 J-GAAP
Mar - Aug, 2024 75,456 9,006 10,788 9,098 122.7 57.1 Oct 10, 2024 J-GAAP
YoY +12.7% +7.3% -7.3% +8.1% +13.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar - Aug, 2024 Guidance ー ー ー ー － 45 Apr 11, 2024 J-GAAP
Mar - Aug, 2024 Results 75,456 9,006 10,788 9,098 122.7 45 Oct 10, 2024 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep - Feb, 2023 74,729 4,771 8,009 5,552 72.2 42.50 Apr 11, 2024 J-GAAP
Sep - Feb, 2024 Guidance 76,544 5,494 8,112 6,702 91.9 45 Oct 10, 2024 J-GAAP
YoY +2.4% +15.2% +1.3% +20.7% +27.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Feb, 2023 128,330 11,599 16,051 11,742 148.0 84.50 Apr 13, 2023 J-GAAP
Feb, 2024 141,706 13,167 19,649 13,969 181.6 85 Apr 11, 2024 J-GAAP
Feb, 2025 Guidance 152,000 14,500 18,900 15,800 216.6 90 Apr 11, 2024 J-GAAP
YoY +7.3% +10.1% -3.8% +13.1% +19.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jun - Aug, 2023 34,881 4,035 5,927 4,368 56.2 11.6 Oct 6, 2023 J-GAAP
Sep - Nov, 2023 35,850 3,850 4,998 3,675 47.5 10.7 Jan 11, 2024 J-GAAP
Dec - Feb, 2023 38,879 921 3,011 1,877 24.4 2.4 Apr 11, 2024 J-GAAP
Mar - May, 2024 35,810 4,149 5,562 4,788 63.9 11.6 Jul 11, 2024 J-GAAP
Jun - Aug, 2024 39,646 4,857 5,226 4,310 58.1 12.3 Oct 10, 2024 J-GAAP
YoY +13.7% +20.4% -11.8% -1.3% +3.4%

Related Articles